Clinical Trials · NCT01242748
A Degarelix Trial in Patients With Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Ferring Pharmaceuticals
- Enrollment
- 288
- Start date
- Oct 2010
- Locations
- 63 sites, 13 countries
- Primary endpoint
- Hazard Ratio of Prostate-specific Antigen (PSA) Progression-free Survival (PFS) Failure Rates During 3 Years' Treatment Between Degarelix and Goserelin